FDA voices concerns over cataracts in children taking Kalydeco
This article was originally published in Scrip
Executive Summary
The US FDA is warning the cystic fibrosis (CF) community about a potential safety concern of cataract development in children with CF taking Vertex Pharmaceuticals' Kalydeco (ivacaftor). The warning stems from recent results from a study in juvenile rats that was conducted to support the treatment of young children less than two years of age with Kalydeco.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.